CCMLC
LGND icon

Cardinal Capital Management LLC (Connecticut)’s Ligand Pharmaceuticals LGND Stock Holding History

Cardinal Capital Management LLC (Connecticut)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-133,672
Closed -$11.3M – 31
2024
Q2 		$11.3M Sell
133,672
-425,563
-76% -$33.9M 3.08% 11
2024
Q1 		$40.9M Buy
559,235
+337,308
+152% +$24.9M 2.05% 22
2023
Q4 		$15.9M Buy
221,927
+15,528
+8% +$916K 0.73% 43
2023
Q3 		$12.4M Sell
206,399
-6,435
-3% -$424K 0.53% 47
2023
Q2 		$15.3M Buy
212,834
+10,841
+5% +$813K 0.58% 48
2023
Q1 		$14.9M Buy
+201,993
New +$14.4M 0.53% 52
2022
Q1 		– Sell
-260,661
Closed -$25.1M – 59
2021
Q4 		$25.1M Sell
260,661
-75,480
-22% -$6.97M 0.59% 51
2021
Q3 		$29.2M Buy
+336,141
New +$26M 0.7% 48
2021
Q1 		– Sell
-1,744,489
Closed -$108M – 59
2020
Q4 		$108M Buy
1,744,489
+235,593
+16% +$13.4M 3.16% 13
2020
Q3 		$89.7M Buy
1,508,896
+116,875
+8% +$7.97M 3.75% 4
2020
Q2 		$97.1M Sell
1,392,021
-182,204
-12% -$11.6M 4.06% 3
2020
Q1 		$71.4M Buy
1,574,225
+99,475
+7% +$5.64M 3.51% 6
2019
Q4 		$95.9M Buy
1,474,750
+42,708
+3% +$2.85M 2.93% 11
2019
Q3 		$88.9M Sell
1,432,042
-5,222
-0.4% -$328K 2.94% 11
2019
Q2 		$102M Buy
1,437,264
+22,592
+2% +$1.66M 3.34% 4
2019
Q1 		$111M Buy
1,414,672
+602,797
+74% +$45.7M 3.69% 5
2018
Q4 		$68.7M Buy
811,875
+273,254
+51% +$29.1M 2.53% 11
2018
Q3 		$84.2M Sell
538,621
-143,034
-21% -$21.6M 2.65% 11
2018
Q2 		$88.1M Sell
681,655
-22,599
-3% -$2.52M 2.88% 7
2018
Q1 		$72.6M Sell
704,254
-344,663
-33% -$34.1M 2.69% 10
2017
Q4 		$89.6M Buy
1,048,917
+49,701
+5% +$4.31M 3.51% 4
2017
Q3 		$84.9M Sell
999,216
-285,496
-22% -$22.6M 3.51% 5
2017
Q2 		$97.3M Buy
1,284,712
+16,471
+1% +$1.15M 3.85% 1
2017
Q1 		$83.7M Buy
1,268,241
+37,963
+3% +$2.5M 3.4% 5
2016
Q4 		$78M Buy
1,230,278
+150,096
+14% +$9.47M 3.35% 6
2016
Q3 		$68.8M Buy
1,080,182
+8,193
+0.8% +$602K 3.19% 7
2016
Q2 		$79.8M Sell
1,071,989
-274,036
-20% -$20.3M 3.95% 2
2016
Q1 		$89.9M Sell
1,346,025
-19,816
-1% -$1.2M 5.02% 1
2015
Q4 		$92.4M Sell
1,365,841
-43,595
-3% -$2.69M 5.34% 1
2015
Q3 		$75.3M Sell
1,409,436
-202,313
-13% -$12.3M 4.71% 1
2015
Q2 		$101M Sell
1,611,749
-59,906
-4% -$3.27M 5.38% 1
2015
Q1 		$80.4M Buy
1,671,655
+91,426
+6% +$3.5M 4.44% 1
2014
Q4 		$52.5M Buy
1,580,229
+78,499
+5% +$2.55M 3.04% 6
2014
Q3 		$44M Buy
1,501,730
+590,907
+65% +$19.6M 2.73% 7
2014
Q2 		$35.4M Sell
910,823
-30,481
-3% -$1.24M 1.91% 19
2014
Q1 		$39.5M Buy
941,304
+11,205
+1% +$467K 2.07% 13
2013
Q4 		$30.5M Buy
+930,099
New +$30.3M 1.63% 18

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Cardinal Capital Management LLC (Connecticut)'s LGND Position: Q3 2024 in Review

Cardinal Capital Management LLC (Connecticut) sold out of Ligand Pharmaceuticals (LGND) in Q3 2024, closing a stake of 133,672 shares — an estimated $11.3M sold.

Cardinal Capital Management LLC (Connecticut) first reported a position in LGND in Q4 2013 and held it in 37 quarters. The position peaked at $111M in Q1 2019. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • Cardinal Capital Management LLC (Connecticut) reported no remaining Ligand Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cardinal Capital Management LLC (Connecticut) sold 133,672 Ligand Pharmaceuticals shares in Q3 2024, an estimated $11.3M.
  • Cardinal Capital Management LLC (Connecticut) first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 37 quarters.
  • Cardinal Capital Management LLC (Connecticut)'s Ligand Pharmaceuticals position peaked at $111M in Q1 2019.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Cardinal Capital Management LLC (Connecticut)'s 13F filing for Q3 2024.